Confirmation of Pharmaco-EEG Predictions Concerning Pharmacodynamic Properties of an Anxiolytic Sedative by Sleep Studies

2015 ◽  
pp. 126-142 ◽  
Author(s):  
B. Saletu ◽  
G. Gr�nberger ◽  
I. St�llberger
Keyword(s):  
Sleep Studies

scholarly journals NeuroTec Sitem-Insel Bern: Closing the Last Mile in Neurology

2021 ◽  
Vol 5 (2) ◽  
pp. 13
Author(s):  
Kaspar A. Schindler ◽  
Tobias Nef ◽  
Maxime O. Baud ◽  
Athina Tzovara ◽  
Gürkan Yilmaz ◽  
...  
Keyword(s):  
Diagnostic Tests ◽  
Current Model ◽  
Disease Process ◽  
Therapeutic Interventions ◽  
Sleep Studies ◽  
Last Mile ◽  
Specialized Equipment ◽  
The One ◽  
Treatment Procedures ◽  
Digital Biomarkers

Neurology is focused on a model where patients receive their care through repeated visits to clinics and doctor’s offices. Diagnostic tests often require expensive and specialized equipment that are only available in clinics. However, this current model has significant drawbacks. First, diagnostic tests, such as daytime EEG and sleep studies, occur under artificial conditions in the clinic, which may mask or wrongly emphasize clinically important features. Second, early detection and high-quality management of chronic neurological disorders require repeat measurements to accurately capture the dynamics of the disease process, which is impractical to execute in the clinic for economical and logistical reasons. Third, clinic visits remain inaccessible to many patients due to geographical and economical circumstances. Fourth, global disruptions to daily life, such as the one caused by COVID-19, can seriously harm patients if access to in-person clinical visits for diagnostic and treatment purposes is throttled. Thus, translating diagnostic and treatment procedures to patients’ homes will convey multiple substantial benefits and has the potential to substantially improve clinical outcomes while reducing cost. NeuroTec was founded to accelerate the re-imagining of neurology and to promote the convergence of technological, scientific, medical and societal processes. The goal is to identify and validate new digital biomarkers that can close the last mile in neurology by enabling the translation of personalized diagnostics and therapeutic interventions from the clinic to the patient’s home.

scholarly journals Preoperative Sleep Studies for Pediatric Adenotonsillectomy

2011 ◽  
Vol 145 (2_suppl) ◽  
pp. P244-P244
Author(s):  
Meenakshi Nayar ◽  
Jason Fleming ◽  
Robynne Wong
Keyword(s):  
Sleep Studies

Electroencephalographic sleep studies in depressed patients during long-term recovery

1993 ◽  
Vol 49 (2) ◽  
pp. 121-138 ◽  
Author(s):  
David J. Kupfer ◽  
Cindy L.Ehlers ◽  
Ellen Frank ◽  
Victoria J. Grochocinski ◽  
Ann B. McEachran ◽  
...  
Keyword(s):  
Sleep Studies ◽  
Depressed Patients

The Use of Sleep Studies in Neurologic Practice

1990 ◽  
Vol 10 (02) ◽  
pp. 111-122 ◽  
Author(s):  
Michael Thorpy ◽  
Peter McGregor
Keyword(s):  
Sleep Studies

scholarly journals Apnea-hypopnea index in sleep studies and the risk of over-simplification

Sleep Science ◽  
2018 ◽  
Vol 11 (1) ◽  
pp. 45-48 ◽  
Author(s):  
Eduardo Borsini ◽  
Facundo Nogueira ◽  
Carlos Nigro
Keyword(s):  
Apnea Hypopnea Index ◽  
Sleep Studies

A Pharmacologic Approach to Sleep Studies

1977 ◽  
pp. 21-62 ◽  
Author(s):  
Wallace B. Mendelson ◽  
J. Christian Gillin ◽  
Richard Jed Wyatt
Keyword(s):  
Sleep Studies

A Sleep Laboratory Evaluation of the Long-Term Efficacy of Zopiclone

1988 ◽  
Vol 33 (2) ◽  
pp. 103-107 ◽  
Author(s):  
Jonathan A.E. Fleming ◽  
Jean Bourgouin ◽  
Peter Hamilton
Keyword(s):  
Sleep Onset ◽  
Sleep Time ◽  
Sleep Efficiency ◽  
Laboratory Evaluation ◽  
Sleep Study ◽  
Sleep Studies ◽  
Metallic Taste ◽  
Hypnotic Medication ◽  
Drug Free

Six patients between the ages of 25 and 59, with chronic, primary insomnia received the new, non-benzodiazepine, hypnotic zopiclone continuously for 17 weeks after a drug free interval of 12 nights. To qualify for the study, sleep efficiency, determined by a sleep study on two, consecutive, placebo-controlled nights, had to be less than 75%. Patients evaluated their sleep by questionnaire and had sleep studies completed throughout active treatment. Zopiclone (7.5 mg) increased sleep efficiency by decreasing sleep latency, wakefulness after sleep onset and increasing total sleep time. Sleep architecture was minimally affected by zopiclone treatment; no significant changes in delta or REM sleep were observed. The commonest side effect was a bitter or metallic taste. No significant changes in biological functioning were noted throughout the study period. These findings indicate that zopiclone is a safe and effective hypnotic medication which maintains its effectiveness with protracted use.

Sign in / Sign up

Export Citation Format

Share Document